Pyruvate kinase M2 (PKM2) improve symptoms of post-ischemic stroke depression by activating VEGF to mediate the MAPK/ERK pathway - PubMed
Pyruvate kinase M2 (PKM2) improve symptoms of post-ischemic stroke depression by activating VEGF to mediate the MAPK/ERK pathway
Yun Feng et al. Brain Behav. 2022 Jan.
Abstract
Purpose: To evaluate and identify the effects and explore the mechanisms of pyruvate kinase M2 (PKM2) on stroke-induced post stroke depression (PSD).
Methods: Rats were separated into six different groups, including sham + saline, Stroke + saline, PSD + saline, PSD + recombinant pyruvate kinase M2 (rPKM2) (112 ng/kg), PSD + rPKM2 (224 ng/kg), and PSD + rPKM2 (224 ng/kg) + bevacizumab. Then, the body weight, sucrose preference rate, immobility time, horizontal movement, and vertical movement were determined to evaluate the effect of PKM2 on improving the depressive behavior of PSD rats. Subsequently, the proliferation of oligodendrocytes in subventricular zone (SVZ) of rats in each group was examined by western blot and immunofluorescent staining. Furthermore, the mRNA and protein expression levels of TNF-α, IL-6, and IL-1β were also detected by qPCR and ELISA to verify the anti-inflammatory effects of PKM2 on PSD rats. In addition, the protein expression levels of MDA, LDH, and NO were tested to reveal that PKM2 can reduce oxidative stress in PSD rats. The western blot and IHC assays were employed to examine the protein expression levels of VEGF, PKM2, and ERK in PSD rats.
Results: In this study, the results showed that PKM2 can improve the depressive behavior and proliferation of oligodendrocytes in PSD rats. In addition, PKM2 has anti-inflammatory and anti-oxidative stress effects on PSD rats. Meanwhile, PKM2 activated the expression level of VEGF/MAPK/ERK pathway.
Conclusion: PKM2 improves symptoms of post-ischemic stroke depression by activating VEGF-mediated MAPK/ERK pathway.
Keywords: ERK; MAPK; PKM2; PSD; VEGF.
© 2021 The Authors. Brain and Behavior published by Wiley Periodicals LLC.
Conflict of interest statement
The authors state that there are no conflicts of interest to disclose.
Figures

PKM2 can improve the depressive behavior of PSD rats. (a) The body weight. (b) The sucrose preference rate in SPT. (c) The immobility time in FST. (d,e) The horizontal movement and vertical movement in OFT of sham, stroke, or PSD rats at indicated time points in response to intranasal administration of saline or PKM2. Data were presented as the mean ± SD with three independent experiments. *p < .05, **p < .01 versus sham group, and ## p < .01 versus PSD group

PKM2 can promote the proliferation of oligodendrocytes in PSD rats. (a) The protein expression levels of MBP and Olig‐2 of rats in each group. (b) The number of MBP and Olig‐2 positive oligodendrocytes in PSD rats. Data were presented as the mean ± SD with three independent experiments. **p < .01 versus sham group and ## p < .01 versus PSD group

PKM2 can reduce the inflammatory response in PSD rats. (a) The mRNA expression levels of TNF‐α, IL‐6, and IL‐1β of rats in each group. (b) The protein expression levels of TNF‐α, IL‐6, and IL‐1β of rats in each group. Data were presented as the mean ± SD with three independent experiments. **p < .01 versus sham group and ## p < .01 versus PSD group

PKM2 can reduce oxidative stress in PSD rats. The protein expression levels of MDA, LDH, and NO of rats in each group. Data were presented as the mean ± SD with three independent experiments. **p < .01 versus sham group and ## p < .01 versus PSD group

PKM2 promotes activation of the MAPK/ERK pathway by activating VEGF expression. (a) The protein levels of PKM2, ERK, and VEGF in PSD rat, as determined using western blotting. Relatively quantitative results were determined by Image J and shown as histogram. (b) IHC assay was applied to examine the protein levels of PKM2, ERK, and VEGF in PSD rat. Data were presented as the mean ± SD with three independent experiments. **p < .01 versus sham group, ## p < .01 versus PSD group, and @@ p < .01 versus PSD + rPKM2 (224 ng/kg) group
Similar articles
-
Chen D, Wei L, Liu ZR, Yang JJ, Gu X, Wei ZZ, Liu LP, Yu SP. Chen D, et al. Neurotherapeutics. 2018 Jul;15(3):770-784. doi: 10.1007/s13311-018-0635-2. Neurotherapeutics. 2018. PMID: 29869055 Free PMC article.
-
PKM2 is involved in neuropathic pain by regulating ERK and STAT3 activation in rat spinal cord.
Wang B, Liu S, Fan B, Xu X, Chen Y, Lu R, Xu Z, Liu X. Wang B, et al. J Headache Pain. 2018 Jan 18;19(1):7. doi: 10.1186/s10194-018-0836-4. J Headache Pain. 2018. PMID: 29349661 Free PMC article.
-
The Role of PKM2 in Multiple Signaling Pathways Related to Neurological Diseases.
Zhang X, Lei Y, Zhou H, Liu H, Xu P. Zhang X, et al. Mol Neurobiol. 2024 Aug;61(8):5002-5026. doi: 10.1007/s12035-023-03901-y. Epub 2023 Dec 29. Mol Neurobiol. 2024. PMID: 38157121 Review.
-
Zhang Y, Yang Y, Li H, Feng Q, Ge W, Xu X. Zhang Y, et al. Mol Neurobiol. 2024 Jan;61(1):132-147. doi: 10.1007/s12035-023-03563-w. Epub 2023 Aug 17. Mol Neurobiol. 2024. PMID: 37592185 Review.
Cited by
-
Shao R, Tan X, Pan M, Huang J, Huang L, Bi B, Huang X, Wang J, Li X. Shao R, et al. Brain Behav. 2024 Jan;14(1):e3387. doi: 10.1002/brb3.3387. Brain Behav. 2024. PMID: 38376033 Free PMC article.
-
Metabolic targeting of platelets to combat thrombosis: dawn of a new paradigm?
Flora GD, Nayak MK, Ghatge M, Chauhan AK. Flora GD, et al. Cardiovasc Res. 2023 Nov 25;119(15):2497-2507. doi: 10.1093/cvr/cvad149. Cardiovasc Res. 2023. PMID: 37706546 Free PMC article. Review.
-
Qiu H, Shen L, Shen Y, Mao Y. Qiu H, et al. Front Neurol. 2023 Jul 17;14:1096911. doi: 10.3389/fneur.2023.1096911. eCollection 2023. Front Neurol. 2023. PMID: 37528851 Free PMC article.
-
Zhao T, Sun S, Gao Y, Rong Y, Wang H, Qi S, Li Y. Zhao T, et al. Heliyon. 2023 Aug 3;9(8):e18622. doi: 10.1016/j.heliyon.2023.e18622. eCollection 2023 Aug. Heliyon. 2023. PMID: 37600392 Free PMC article.
-
Chen X, Shen J, Zhou Q, Jin X, Liu H, Gao R. Chen X, et al. Pharmaceuticals (Basel). 2022 Dec 13;15(12):1551. doi: 10.3390/ph15121551. Pharmaceuticals (Basel). 2022. PMID: 36559001 Free PMC article.
References
-
- Chen, D. , Wei, L. , Liu, Z. R. , Yang, J. J. , Gu, X. , Wei, Z. Z. , Liu, L. P. , & Yu, S. P. (2018). Pyruvate kinase M2 increases angiogenesis, neurogenesis, and functional recovery mediated by upregulation of STAT3 and focal adhesion kinase activities after ischemic stroke in adult mice. Neurotherapeutics, 15(3), 770–784. 10.1007/s13311-018-0635-2 - DOI - PMC - PubMed
-
- Cheng, Y. , Feng, Y. , Xia, Z. , Li, X. , & Rong, J. (2017). ω‐Alkynyl arachidonic acid promotes anti‐inflammatory macrophage M2 polarization against acute myocardial infarction via regulating the cross‐talk between PKM2, HIF‐1α and iNOS. Biochimica et Biophysica Acta ‐ Molecular and Cell Biology of Lipids, 1862(12), 1595–1605. 10.1016/j.bbalip.2017.09.009 - DOI - PubMed
-
- Desai, S. , Ding, M. , Wang, B. , Lu, Z. , Zhao, Q. , Shaw, K. , , Yung, W. K. A. , Weinstein, J. N. , Tan, M. , & Yao, J. (2014). Tissue‐specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. Oncotarget, 5(18), 8202–8210. doi: 10.18632/oncotarget.1159 - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous